Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtaiBeckley Inc. (NASDAQ: ATAI) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. AtaiBeckley, a clinical-stage biopharmaceutical and biotechnology company focused on mental health treatments, uses SEC reports to disclose material events, financing activities, corporate transactions and updates related to its clinical pipeline.
Investors researching ATAI can review current and historical filings such as Form 8-K reports that describe significant developments. Recent 8-K filings have addressed topics including the completion of the acquisition of Beckley Psytech Limited and the resulting name change to Atai Beckley N.V., public offerings of common shares to fund clinical programs, FDA Breakthrough Therapy designation for BPL-003 in treatment-resistant depression, and the redomiciliation process that led to AtaiBeckley Inc. becoming a Delaware corporation. Other filings detail shareholder votes on the Beckley Psytech transaction and redomiciliation, as well as prospectus supplements related to registered offerings and resales.
Through this page, users can also locate references to AtaiBeckley’s financial reporting, such as earnings press releases furnished on Form 8-K, and legal or transactional documents filed as exhibits, including share purchase agreements and underwriting agreements. These materials help explain how AtaiBeckley finances the development of its key programs BPL-003, VLS-01 and EMP-01 and how it structures its corporate operations.
Stock Titan enhances the ATAI filings page with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure new AtaiBeckley filings appear promptly, while dedicated sections make it easier to find items such as current reports, registration statements and, when available, insider transaction reports on Form 4. This combination of raw filings and AI-generated insights can support deeper due diligence on AtaiBeckley’s regulatory and financial disclosures.
Atai Beckley N.V. (ATAI) reported an insider transaction: a director acquired 7,702,990 common shares on November 5, 2025. The filing notes this occurred in connection with the Issuer’s completion of its acquisition of Beckley Psytech, for which an aggregate of 103,000,066 common shares were issued as consideration or as underlying replacement awards.
The director also received two stock option grants with a $4.48 exercise price, covering 103,000 and 40,400 shares, each expiring on November 5, 2035. One option vests in full on the first anniversary of the grant date, and the other vests in 12 substantially equal monthly installments beginning December 5, 2025. Following the transactions, the director held 7,702,990 common shares directly.
Atai Beckley N.V. (ATAI) reported a director’s Form 4 reflecting a new stock option grant. On 11/04/2025, the director was granted 56,818 stock options with an exercise price of $5.28 per share. The option expires on 11/04/2035 and will vest as to 100% of the underlying shares on the first anniversary of the grant date.
Following the reported transaction, the director beneficially owned 56,818 derivative securities, held directly. The filing notes the transaction code “A,” indicating an option grant.
Atai Beckley N.V. (ATAI) reported an insider status update: a director filed a Form 3 for an event dated 11/05/2025.
The filing states no securities are beneficially owned. It was filed by one reporting person, with execution by an attorney-in-fact pursuant to Exhibit 24 (Power of Attorney).
Atai Beckley N.V. (ATAI) insider filing: A director filed an initial Form 3 reflecting their status as a board member as of 11/05/2025. The filing states that no securities are beneficially owned by the reporting person at this time. The form was submitted by attorney-in-fact Ryan Barrett under a Power of Attorney (Exhibit 24). This is an administrative disclosure establishing insider reporting status and current holdings.
Atai Beckley N.V. filed a prospectus supplement covering the resale from time to time by certain selling securityholders of up to 5,316,238 common shares. The registration satisfies rights granted in connection with the Company’s acquisition of the issued share capital of Beckley Psytech Limited not already owned by the Company.
The Company also filed a legal opinion from NautaDutilh N.V. as Exhibit 5.1 regarding the validity of the shares, along with a related consent and the cover page interactive data file.
ATAI Life Sciences filed a prospectus supplement to register for resale up to 5,316,238 common shares previously issued to selling securityholders in connection with the acquisition of Beckley Psytech. The shares may be sold from time to time by the holders using various methods described in the document.
ATAI will not receive proceeds from sales by the selling securityholders, though it will cover certain registration expenses. The shares trade on the Nasdaq Global Market under the symbol ATAI. As context, shares outstanding were 363,114,450 as of November 5, 2025.
The resale registration lists individual holder amounts, including Shlomi Raz 3,268,819 and Cantor Fitzgerald & Co. 900,901. Sales may occur through underwriters, dealers, agents, or direct transactions at market, related, fixed, or negotiated prices.
Atai Beckley N.V. (NASDAQ: ATAI) completed its previously announced acquisition of the issued share capital of Beckley Psytech Limited not already owned by the company. The transaction closed on November 5, 2025 and was executed under the June 2, 2025 Share Purchase Agreement, as amended.
As consideration, the company issued an aggregate of 103,000,066 ordinary shares, delivered directly as share consideration or as underlying replacement awards to Beckley Psytech shareholders, certain consultants, and equity award holders. In connection with closing, the company changed its name to Atai Beckley N.V.
The company furnished a press release announcing completion of the acquisition as Exhibit 99.1.
atai Life Sciences (ATAI) reported shareholder approvals tied to its proposed Beckley Psytech acquisition and corporate reorganization. Holders approved the Acquisition Proposal with 121,090,088 votes for, and authorized the related share issuance under Nasdaq Rule 5635(a) with 120,951,244 votes for. Shareholders also elected Cosmo Feilding-Mellen and Dr. Robert Hershberg as non-executive directors and approved governing document changes.
Steps toward redomiciliation advanced, including approval of a merger with atai Life Sciences Luxembourg S.A. and related charter amendments addressing withdrawal-right cash compensation and potential B share conversion. As of October 7, 2025, shares outstanding were 240,488,841; 156,318,136 shares were present or represented at the meeting. Completion of the redomiciliation remains subject to closing conditions.
ATAI Life Sciences amended its Share Purchase Agreement for the Beckley Psytech acquisition. The amendment reduces the consideration by 1,221,712 atai shares on a pro‑rata basis, with a revised total of 103,823,190 atai shares to be distributed to Beckley shareholders or to underlie Replacement Awards for certain optionholders.
The amendment also allocates 900,901 atai shares to Cantor Fitzgerald & Co. for advisory services. These CF&CO shares will have no lock‑up and will be registered for resale on a prospectus supplement to be filed immediately following closing. Definitions for “Buyer Share Price” and “VWAP” were updated, and leakage provisions clarify that certain Transaction or Carve‑out Costs up to $6,780,500 may be settled via pro‑rata share reductions.
Consideration Shares and applicable Replacement Awards remain subject to lock‑up covenants, with limited discretionary releases of up to 0.75% to cover certain tax obligations. Shareholders must notify atai to attend the Extraordinary General Meeting by 5:00 p.m. CET on October 31, 2025.
ATAI Life Sciences amended its share purchase agreement for the Beckley Psytech acquisition. The amendment reduces the consideration to Beckley shareholders by an aggregate of 1,221,712 atai Shares, with a total of 103,823,190 atai Shares now to be distributed to Beckley shareholders or to underlie Replacement Awards for certain optionholders.
The amendment also provides that 900,901 atai Shares will be issued to Cantor Fitzgerald & Co. for advisory services to Beckley Psytech. These shares will not be subject to lock-up and will be registered for resale on a prospectus supplement filed immediately following closing. The filing updates “Permitted Costs” and leakage mechanics, including that certain leakage up to $6,780,500 may be settled via pro‑rata reductions in Consideration Shares. Lock-up terms remain in place, with atai able to allow up to 0.75% of Consideration Shares to be released to cover tax obligations.
The company also reminded shareholders of Extraordinary General Meeting attendance procedures tied to the October 31, 2025 notification deadline.